Author:
Kwon Mi Sun,Kim Jin Young,Kim Yu Min,Do Jae Rock,Kang Yong Koo,Shin Jae Pil,Park Dong Ho
Abstract
Purpose: To evaluate the efficacy of topical bromfenac combined with intravitreal aflibercept (IVA) injection in the treatment of exudative age-related macular degeneration over a 2-year period.Methods: We retrospectively studied 43 patients (43 eyes) with exudative age-related macular degeneration. Patients were included if they received IVA injections under an as-needed protocol and had > 2 years of follow-up. Among the 43 eyes, 25 received only IVA (IVA group), whereas 18 received a combination of IVA and topical bromfenac (bromfenac group). The primary outcome measure was the total number of IVA injections administered over 2 years from the initial injection compared between groups. We also compared changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) between groups.Results: The bromfenac group received a significantly lower number of IVA injections over 2 years (7.4 ± 1.0), compared with the IVA group (9.0 ± 1.9) (<i>p</i> < 0.01). Both groups showed improvements in BCVA and CRT after 2 years compared with their baseline values. However, changes in BCVA and CRT at 2 years did not significantly differ between groups (<i>p</i> = 0.786 and <i>p</i> = 0.905, respectively).Conclusions: Among patients with exudative age-related macular degeneration, the total number of IVA injections over 2 years was lower in the bromfenac group than in the IVA group. More studies are needed to confirm the efficacy of topical bromfenac in a combined treatment regimen.
Funder
National Research Foundation of Korea
Ministry of Science and ICT
Information Technology Research Center
Institute of Information and Communications Technology Planning and Evaluation
Korea Drug Development Fund
Ministry of Trade, Industry and Energy
Ministry of Health and Welfare
Korea Health Industry Development Institute
Publisher
Korean Ophthalmological Society